Femasys

FEMY

Medical - Instruments & Supplies · Healthcare

Price

$2.96

+0.23 (+8.42%)

Market Cap

$8.9M

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Good

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+235.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 590K (2021) → 2.0M (2025)

Winston Score History

The full picture

Femasys Inc. is a small medical device company focused on women's reproductive health. Its main product is FemBloc, a permanent birth control device designed to block the fallopian tubes without surgery. The company also has FemaSeed, a device used to help with intrauterine insemination for fertility treatments. Its customers are primarily gynecologists and women's health clinics in the United States.

Femasys makes money by selling its medical devices to healthcare providers. The company is very small, with a market cap near zero, and is still in early commercial stages, meaning it spends far more than it earns — reflected in its deeply negative operating margin. FemBloc still requires full FDA approval for its permanent contraception indication, which is the single biggest factor that will determine whether the company can grow or faces serious financial trouble ahead.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-18.9% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+58.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$8M/ year

↓ Declining (-8% vs prior year)

330.4% of revenue

18.4x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

17.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

$1M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Femasys has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-8.2%

Thin — -8.2% gross margin

Profit after running costs

Operating Margin

-1526.7%

Losing money on operations — -1526.7%

Return on the money invested

ROCE

-232.6%

Weak — -232.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+21.9%

Fast-growing sales (+21.9% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-788.0%

Burning cash (-788.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.87

Moderate — manageable debt (0.87)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial